{"filing":{"accession_number":"0001395064-26-000187","cik":"0001395064","ticker":"TKPHF","company_name":"TAKEDA PHARMACEUTICAL CO LTD","form":"6-K","filing_date":"2026-06-26","report_date":null,"primary_document":"form6k_062626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000187/form6k_062626.htm"},"events":[{"id":14095,"run_id":12534,"accession_number":"0001395064-26-000187","anchor_item_number":"EX-99.1","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This exhibit discloses the results of voting at Takeda's 150th Annual General Meeting of Shareholders held on June 24, 2026, including approval votes on five proposals: dividend appropriation, election of eight directors (non-audit committee), election of three audit committee directors, election of a substitute audit committee director, and director bonuses. The document provides detailed voting tallies (approval, against, abstention) and approval percentages for each proposal, meeting the definition of shareholder_vote_results under Item 5.07 equivalent disclosure.","company_name":"TAKEDA PHARMACEUTICAL CO LTD","ticker":"TKPHF","filing_date":"2026-06-26","form":"6-K","submitted_at":null,"items":[{"id":11429,"accession_number":"0001395064-26-000187","item_number":"EX-99.1","item_title":"extraordinary_report.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This exhibit discloses the results of voting at Takeda's 150th Annual General Meeting of Shareholders held on June 24, 2026, including approval votes on five proposals: dividend appropriation, election of eight directors (non-audit committee), election of three audit committee directors, election of a substitute audit committee director, and director bonuses. The document provides detailed voting tallies (approval, against, abstention) and approval percentages for each proposal, meeting the definition of shareholder_vote_results under Item 5.07 equivalent disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-26T10:33:37.428316+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11429,"accession_number":"0001395064-26-000187","item_number":"EX-99.1","item_title":"extraordinary_report.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This exhibit discloses the results of voting at Takeda's 150th Annual General Meeting of Shareholders held on June 24, 2026, including approval votes on five proposals: dividend appropriation, election of eight directors (non-audit committee), election of three audit committee directors, election of a substitute audit committee director, and director bonuses. The document provides detailed voting tallies (approval, against, abstention) and approval percentages for each proposal, meeting the definition of shareholder_vote_results under Item 5.07 equivalent disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-26T10:33:37.428316+00:00","company_name":"TAKEDA PHARMACEUTICAL CO LTD","ticker":"TKPHF","filing_date":"2026-06-26"}]}